

Remarks

Claims 1-20 are pending in this application. Claims 1-20 are cancelled herein. Claim 21 and 22 are added herein. Accordingly, claims 21 and 22 are now pending in this application.

Objections to the Specification and Claims

The Title has been amended as requested by the Examiner.

Rejection under 35 USC § 112 – 1st Paragraph

The Office Action has rejected claims 1-20 under 35 U.S.C. 112, 1st paragraph as not being enabled. Applicants note that claims 1-20 are cancelled herein. Accordingly, applicants believe the rejections are mooted by cancellation of claims 1-20 and respectfully request that the rejections be withdrawn.

Rejection under 35 USC § 103

Claims 1-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Effland (US Pat. No. 4,970,219) in view of Majno (Amer J Path 1998, 153, 1035-1039). Applicants again note that claims 1-20 are cancelled herein. Accordingly, applicants believe the rejections are mooted by cancellation of claims 1-20 and respectfully request that the rejections be withdrawn.

Conclusion

The points and concerns of the Examiner have been addressed in full. Applicants respectfully submit that the instant application is in condition for allowance, which is respectfully requested. Should any issues remain unresolved in this application which would bar issuance, the Examiner is invited to contact the undersigned Attorney at (919) 483-6334 to discuss such issues.

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to affect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,


John L. Lemanowicz
Attorney for Applicants
Registration No. 37,380

Date: 4 September, 2008

Glaxo Smith Kline
Five Moore Drive, PO Box 13398
Research Triangle Park, North Carolina 27709
(919) 483-8247